{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:12:23Z","timestamp":1793106743002,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471721"],"award-info":[{"award-number":["81471721"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81471722"],"award-info":[{"award-number":["81471722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771887"],"award-info":[{"award-number":["81771887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771897"],"award-info":[{"award-number":["81771897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004602","name":"Program for New Century Excellent Talents in University","doi-asserted-by":"publisher","award":["NCET-13-0386"],"award-info":[{"award-number":["NCET-13-0386"]}],"id":[{"id":"10.13039\/501100004602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s10741-018-9755-3","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:25:32Z","timestamp":1544055932000},"page":"325-333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Protective role of beta-blockers in chemotherapy-induced cardiotoxicity\u2014a systematic review and meta-analysis of carvedilol"],"prefix":"10.1007","volume":"24","author":[{"given":"Shan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-yue","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-ting","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8437-9887","authenticated-orcid":false,"given":"Ying-kun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"issue":"5","key":"9755_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3322\/canjclin.40.5.318","volume":"40","author":"DL Lamm","year":"2010","unstructured":"Lamm DL (2010) Cancer statistics. Ca A Cancer J Clin 40(5):318\u2013319","journal-title":"Ca A Cancer J Clin"},{"issue":"19","key":"9755_CR2","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/jnci\/djn310","volume":"100","author":"AC Mertens","year":"2008","unstructured":"Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y (2008) Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. J Natl Cancer Inst 100(19):1368\u20131379. \n                    https:\/\/doi.org\/10.1093\/jnci\/djn310","journal-title":"J Natl Cancer Inst"},{"key":"9755_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/COC.0b013e318142c865","volume":"31","author":"XL Du","year":"2008","unstructured":"Du XL, Fox EE, Lai D (2008) Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Am J Clin Oncol 31:105\u2013116. \n                    https:\/\/doi.org\/10.1097\/COC.0b013e318142c865","journal-title":"Am J Clin Oncol"},{"key":"9755_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","volume":"32","author":"EA Lefrak","year":"1973","unstructured":"Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302\u2013314","journal-title":"Cancer"},{"key":"9755_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2013.51.1261","volume":"32","author":"I Vazluis","year":"2014","unstructured":"Vazluis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA (2014) Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 32:927\u2013934. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.51.1261","journal-title":"J Clin Oncol"},{"issue":"24","key":"9755_CR6","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long J, Steingart R, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504\u20132512. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2012.07.068","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 5","key":"9755_CR7","doi-asserted-by":"publisher","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","volume":"21","author":"D Bovelli","year":"2010","unstructured":"Bovelli D, Plataniotis G, Roila F, Group EGW (2010) Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 21(Suppl 5):v277. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdq200","journal-title":"Ann Oncol"},{"issue":"3","key":"9755_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik JL, Byers T, Diguiseppi C, Dabelea D, Denberg TD (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13(3):1\u20139. \n                    https:\/\/doi.org\/10.1186\/bcr2901.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"9755_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1634\/theoncologist.2010-0348","volume":"16","author":"C Shenoy","year":"2011","unstructured":"Shenoy C, Klem I, Crowley AL, Patel MR, Winchester MA, Owusu C, Kimmick GG (2011) Cardiovascular complications of breast cancer therapy in older adults. Oncologist 16(8):1138\u20131143. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2010-0348","journal-title":"Oncologist"},{"issue":"11","key":"9755_CR10","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869\u20132879. \n                    https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"6","key":"9755_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","volume":"113","author":"B Ky","year":"2013","unstructured":"Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ (2013) Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res 113(6):754\u2013764. \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.300218","journal-title":"Circ Res"},{"issue":"3","key":"9755_CR12","doi-asserted-by":"publisher","first-page":"CD005006","DOI":"10.1002\/14651858.CD005006.pub4.","volume":"6","author":"EV Dalen","year":"2006","unstructured":"Dalen EV, Michiels EM (2006) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 6(3):CD005006. \n                    https:\/\/doi.org\/10.1002\/14651858.CD005006.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"9755_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","volume":"37","author":"P Spallarossa","year":"2004","unstructured":"Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, Rossettin P, Ghigliotti G, Ballestrero A, Patrone F (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37(4):837\u2013846. \n                    https:\/\/doi.org\/10.1016\/j.yjmcc.2004.05.024","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"9755_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1006\/taap.2002.9532","volume":"185","author":"DL Santos","year":"2002","unstructured":"Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB (2002) Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 185(3):218\u2013227","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"9755_CR15","first-page":"e86","volume":"15","author":"NS Rehsia","year":"2010","unstructured":"Rehsia NS, Dhalla NS (2010) Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. Exp Clin Cardiol 15(4):e86\u2013e95","journal-title":"Exp Clin Cardiol"},{"issue":"1 Suppl 1","key":"9755_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0033-0620(98)80027-3","volume":"41","author":"G Feuerstein","year":"1998","unstructured":"Feuerstein G, Yue TL, Ma X, Ruffolo RR (1998) Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 41(1 Suppl 1):17\u201324","journal-title":"Prog Cardiovasc Dis"},{"issue":"4","key":"9755_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/HJH.0b013e3280127948","volume":"25","author":"P Dandona","year":"2007","unstructured":"Dandona P, Ghanim H, Brooks DP (2007) Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens 25(4):731\u2013741. \n                    https:\/\/doi.org\/10.1097\/HJH.0b013e3280127948","journal-title":"J Hypertens"},{"issue":"11","key":"9755_CR18","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0006-2952(99)00262-2","volume":"58","author":"O Jonsson","year":"1999","unstructured":"Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K (1999) Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol 58(11):1801\u20131806","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"9755_CR19","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med"},{"key":"9755_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, Cochrane Bias Methods Group, Cochrane Statistical Methods Group (2011) The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928\u2013d5928. \n                    https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"9755_CR21","unstructured":"Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0"},{"key":"9755_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101\u2013breast): a randomized trial for the prevention of Trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013877. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.68.7830","journal-title":"J Clin Oncol"},{"key":"9755_CR23","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland \u00c5, Stor\u00e5s TH, Hagve TA, R\u00f8sj\u00f8 H, Steine K, Geisler J, Omland T (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671\u20131680. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw022","journal-title":"Eur Heart J"},{"key":"9755_CR24","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"N Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, Oguzhan A, Eryol NK, Topsakal R, Ergin A, Inanc T (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258\u20132262. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2006.07.052","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"9755_CR25","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","volume":"144","author":"R Jhorawat","year":"2016","unstructured":"Jhorawat R, Kumari S, Varma SC, Rohit MK, Narula N, Suri V, Malhotra P, Jain S (2016) Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res 144(5):725","journal-title":"Indian J Med Res"},{"key":"9755_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","volume":"21","author":"A Elitok","year":"2014","unstructured":"Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, Bugra Z, Mercanoglu F, Oncul A, Oflaz H (2014) Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J 21:509\u2013515. \n                    https:\/\/doi.org\/10.5603\/CJ.a2013.0150","journal-title":"Cardiol J"},{"issue":"5","key":"9755_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","volume":"69","author":"M Nabati","year":"2017","unstructured":"Nabati M, Janbabai G, Baghyari S, Esmaili M, Yazdani J (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69(5):279\u2013285. \n                    https:\/\/doi.org\/10.1097\/FJC.0000000000000470","journal-title":"J Cardiovasc Pharmacol"},{"key":"9755_CR28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","volume":"71","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley Junior MR et al (2018) Carvedilol for prevention of chemotherapy related cardiotoxicity. J Am Coll Cardiol 71:2281\u20132290. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049","journal-title":"J Am Coll Cardiol"},{"key":"9755_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.15420\/ahhj.2011.9.2.95","volume":"9","author":"R Salehi","year":"2011","unstructured":"Salehi R, Zamani B, Esfehani A et al (2011) Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma. Am Heart Hosp J 9:95. \n                    https:\/\/doi.org\/10.15420\/ahhj.2011.9.2.95","journal-title":"Am Heart Hosp J"},{"issue":"5","key":"9755_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11886-013-0362-6","volume":"15","author":"A Colombo","year":"2013","unstructured":"Colombo A, Cipolla C, Beggiato M, Cardinale D (2013) Cardiac toxicity of anticancer agents. Curr Cardiol Rep 15(5):1\u201311. \n                    https:\/\/doi.org\/10.1007\/s11886-013-0362-6.","journal-title":"Curr Cardiol Rep"},{"key":"9755_CR31","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","volume":"91","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Abraham I (2015) Cardioprotective role of \u03b2-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J 91:627\u2013633. \n                    https:\/\/doi.org\/10.1136\/postgradmedj-2015-133535","journal-title":"Postgrad Med J"},{"key":"9755_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","volume":"26","author":"K Negishi","year":"2013","unstructured":"Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26:493\u2013498. \n                    https:\/\/doi.org\/10.1016\/j.echo.2013.02.008","journal-title":"J Am Soc Echocardiogr"},{"key":"9755_CR33","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/S0735-1097(16)31530-3","volume":"67","author":"CR Manrique","year":"2016","unstructured":"Manrique CR, Spinetto PV, Tiwari N, Romero J, Jorde U, Garcia M (2016) Protective effect of beta-blockers on chemotherapy induced cardiomyopathy: a meta-analysis of prospective studies. J Am Coll Cardiol 67:1529. \n                    https:\/\/doi.org\/10.1016\/S0735-1097(16)31530-3","journal-title":"J Am Coll Cardiol"},{"key":"9755_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/ehjci\/jex159","volume":"19","author":"SL Heck","year":"2017","unstructured":"Heck SL, Gulati G, Hoffmann P, von Knobelsdorff-Brenkenhoff F, Stor\u00e5s TH, Ree AH, Gravdehaug B, R\u00f8sj\u00f8 H, Steine K, Geisler J, Schulz-Menger J, Omland T (2017) Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. Eur Heart J - Cardiovasc Imaging 19:544\u2013552. \n                    https:\/\/doi.org\/10.1093\/ehjci\/jex159","journal-title":"Eur Heart J - Cardiovasc Imaging"},{"key":"9755_CR35","doi-asserted-by":"publisher","unstructured":"Diao K, Yang Z, Xu H, Liu X, Zhang Q, Shi K, Jiang L, Xie LJ, Wen LY, Guo YK (2017) Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis. J Cardiovasc Magn Reson 18. \n                    https:\/\/doi.org\/10.1186\/s12968-016-0313-7\n                    \n                  .","DOI":"10.1186\/s12968-016-0313-7"},{"key":"9755_CR36","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ijcard.2012.06.023","volume":"167","author":"MG Kaya","year":"2013","unstructured":"Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, Kalay N, Dikilitas M, Yarlioglues M, Karaca H, Berk V, Ardic I, Ergin A, Lam YY (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 167:2306\u20132310. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2012.06.023","journal-title":"Int J Cardiol"},{"key":"9755_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, Karavidas A, Anagnostopoulos N, Marinakis T, Galanopoulos A, Georgiakodis F, Zimeras S, Kyriakidis M, Ahimastos A (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 85:894\u2013896. \n                    https:\/\/doi.org\/10.1002\/ajh.21840","journal-title":"Am J Hematol"},{"key":"9755_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"DM Gujral","year":"2018","unstructured":"Gujral DM, Lloyd G, Bhattacharyya S (2018) Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy \u00b1 trastuzumab. Breast 37:64\u201371. \n                    https:\/\/doi.org\/10.1016\/j.breast.2017.10.010","journal-title":"Breast"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9755-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10741-018-9755-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-018-9755-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T19:13:33Z","timestamp":1575573213000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10741-018-9755-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["9755"],"URL":"https:\/\/doi.org\/10.1007\/s10741-018-9755-3","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"value":"1382-4147","type":"print"},{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,6]]},"assertion":[{"value":"6 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}